By Sabela Ojea
Incyte and Syndax Pharmaceutical said the Food and Drug Administration approved their graft disease treatment Niktimvo antibody in nine milligram and 22 milligram vial sizes.
The biopharmaceutical companies on Wednesday said that they expect the product to be available for order in the U.S. early in February. Incyte has exclusive commercialization rights for Niktimvo outside the U.S.
Niktimvo was approved by the FDA on Aug. 14 for the treatment of chronic graft-versus-host disease after failure of at least two prior lines of systemic therapy in adult and pediatric patients weighing at least 40 kilograms. Graft-versus-host disease is a severe complication that can occur following hematopoietic stem cell transplantation.
Write to Sabela Ojea at sabela.ojea@wsj.com
(END) Dow Jones Newswires
January 15, 2025 18:12 ET (23:12 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。